MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.490
+0.190
+8.26%
After Hours: 2.480 -0.01 -0.40% 16:00 09/25 EDT
OPEN
2.330
PREV CLOSE
2.300
HIGH
2.540
LOW
2.290
VOLUME
173.80K
TURNOVER
--
52 WEEK HIGH
4.240
52 WEEK LOW
1.330
MARKET CAP
59.24M
P/E (TTM)
-5.3699
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insider Buys Anixa Biosciences Shares
Shares of Anixa Biosciences Inc (NASDAQ:ANIX) moved higher by 9.6% from the previous closing price. A Form 4 filing filed with the SEC on Monday, September 14 showed that Titterton Lewis H Jr bought 40,000 shares at an average price of $2.08.
Benzinga · 09/14 15:43
Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual 2020 H.C. Wainwright Global Investment Conference being held
PR Newswire · 09/08 12:00
SWBI, ONVO, YRCW and PTI among midday movers
Gainers: Viveve Medical (NASDAQ:VIVE) +111%. VivoPower International (NASDAQ:VVPR) +57%. Sigma Labs (NASDAQ:SGLB) +27%. FTS International (NYSEMKT:FTSI) +2
Seeking Alpha - Article · 08/25 16:47
Anixa Biosciences, Co. Partner, OntoChem, Report Have Identified Added Candidates Through In Silico Screening Study
 Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional
Benzinga · 08/13 13:04
Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
Benzinga · 07/28 13:10
Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its prophylactic breast cancer vaccine is making progress towards clinical trials.
PR Newswire · 07/28 13:00
Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to supp
PR Newswire · 07/20 13:00
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Benzinga · 07/10 12:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIX. Analyze the recent business situations of Anixa Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIX stock price target is 8.75 with a high estimate of 9.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 1.62M
% Owned: 6.82%
Shares Outstanding: 23.79M
TypeInstitutionsShares
Increased
6
204.81K
New
8
21.77K
Decreased
4
12.75K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.03%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Director
Amit Kumar
Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Michael Catelani
Executive Vice President
Thomas Schlumpberger
Lead Director/Independent Director
Lewis Titterton
Independent Director
John Monanhan
Independent Director
Arnold Baskies
Independent Director
David Cavalier
Independent Director
Emily Gottschalk
Independent Director
John Monahan
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.